BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform

Published:
May 30, 2019

We are excited to announce that on May 30, 2019, BioLoomics closed a $600,000 pre-seed round of funding with private investors to develop and launch our platform technology, and produce libraries of robust biosensor assays to improve the clinical success rate of drug development pipelines. By using single live cells as test tubes, we are actively scaling high throughput screening techniques to approach the vastness of protein chemical space. 

Dr. Douglas Chapnick, BioLoomics Founder and CEO, was a postdoctoral candidate in the Biochemistry Department in Dr. Xuedong Lui’s lab at the University of Colorado, Boulder. For the past five years he has been a key team member in Dr. Will Old’s Rapid Threat Assessment project, funded by DARPA. Within the RTA project, Dr. Chapnick built pipelines to rapidly understand the effects of chemical and biochemical threats on living cells utilizing genetically encoded Forster Resonance Energy Transfer (FRET) biosensors to assess each threat’s effect on biochemical pathways. As the RTA project came to a close, Dr. Chapnick formed BioLoomics to apply similar techniques in the pharmaceutical industry, and began generating large libraries of biosensors with pathway specificity and high dynamic range. 

Jeremy Jacobsen is also joining the BioLoomics team after his tenure in the DARPA Rapid Threat Assessment project. He is a bioinformatics expert and master of mechanical engineering who specializes in large multidimensional datasets and has applied this expertise to proteomics, metabolomics, and microscopy data. Jeremy will immediately begin developing proprietary software and hardware to enable us to select unique biosensors in individual cells.  

We are setting up our first facility in a space generously offered by Dr. Michael Stowell and the University of Colorado department of Molecular, Cellular, and Developmental Biology. 

We’re grateful for the support of our early investors, and to the University of Colorado and its accelerator programs, including Venture Partners, and the Lab Venture Challenge.

Written by

View More News

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

October 15, 2024

BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs

Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs

October 15, 2024
View News Article

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

June 13, 2024

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

BioLoomics’ goal is to make a degrader from an antibody in one month

June 13, 2024
View News Article

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

June 13, 2024

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

Our mission is to make safer, more effective cancer therapeutics.

June 13, 2024
View News Article

Pre-Seed Extension

June 13, 2024

Pre-Seed Extension

BioLoomics closed a $575,000 round of pre seed extension funding on May 11, 2021..

June 13, 2024
View News Article

OEDIT Grant Award

June 13, 2024

OEDIT Grant Award

The Colorado OEDIT provides funding opportunities to small businesses in fourteen industries...

June 13, 2024
View News Article

BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform

June 13, 2024

BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform

We are excited to announce that on May 30, 2019, BioLoomics closed a $600,000 pre-seed round...

June 13, 2024
View News Article
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.